Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney | Zendy

Yasutaka Yamamoto | Zendy; Masayuki Iyoda | Zendy; Shohei Tachibana | Zendy; Kei Matsumoto | Zendy; Yukihiro Wada | Zendy; Taihei Suzuki | Zendy; Ken Iseri | Zendy; Tomohiro Saito | Zendy; Kei Fukuda-Hihara | Zendy; Takanori Shibata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney

Author(s) -

Yasutaka Yamamoto,

Masayuki Iyoda,

Shohei Tachibana,

Kei Matsumoto,

Yukihiro Wada,

Taihei Suzuki,

Ken Iseri,

Tomohiro Saito,

Kei Fukuda-Hihara,

Takanori Shibata

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx264

Subject(s) - erlotinib , medicine , kidney disease , glomerulosclerosis , epidermal growth factor receptor , kidney , endocrinology , renal function , proteinuria , cancer research , pharmacology , cancer

Increasing evidence indicates that epidermal growth factor receptor (EGFR) has a pathogenic role in renal fibrosis. Currently no effective treatment can completely halt the progression of chronic kidney disease (CKD). This study was undertaken to investigate the renoprotective effects of erlotinib, a tyrosine kinase inhibitor that can block EGFR activity in the progression of CKD and the mechanisms involved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research